Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
prolactinoma/triglyceride
Nuoroda įrašoma į mainų sritį
Puslapis 1 nuo 19 rezultatus
[Serum concentrations of glucose, cholesterol and triglycerides in men with prolactinoma treated with cabergoline].
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
OBJECTIVE
Increasing evidence exists that hyperprolactinemia alters metabolic profile. The mechanism of this effect is unknown. We aimed to investigate the differences between the metabolic profile of patients with prolactinomas and nonfunctional pituitary adenomas and to evaluate the impact of
Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Previous studies suggest that hyperprolactinaemia might have adverse effects on lipid and glucose metabolism. We therefore aimed to evaluate whether dopamine agonist treatment with cabergoline has significant effects on blood lipids, fasting glucose and HbA1c levels in patients with micro- or
BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: a pilot study in a Chinese cohort.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Deranged metabolic profiles and insulin resistance (IR) have been documented in patients with prolactinomas. Few data are yet available on the apolipoprotein (apo) B/apoA-I ratio and its relationship with IR in patients with prolactinomas. This study was aimed to evaluate the level of apoB/apoA-I
Hyperprolactinemia has no effect on plasma ghrelin levels in patients with prolactinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
OBJECTIVE
Accumulating evidence suggests that prolactin is a modulator of body weight and composition and that it regulates some transporters in adipose tissue. It was demonstrated that hyperprolactinemia is associated with weight gain and obesity. Ghrelin is a novel hormone secreted from many
Preclinical atherosclerosis in patients with prolactinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
OBJECTIVE
The aim of this study was to evaluate the effect of hyperprolactinemia on body fat, insulin sensitivity, inflammatory markers, and cardiovascular risk in patients with prolactinoma.
METHODS
The study included 35 untreated hyperprolactinemic patients with pituitary adenomas, and 36 age-,
Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Serum total cholesterol and triglyceride levels were determined in forty-seven women with prolactinoma and in eighty-four age- and weight-matched control women. Oral glucose tolerance tests (OGTT) were performed and postheparin plasma lipoprotein lipase (LPL) and hepatic lipase (HL) activities were
Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Although bromocriptine is the mainstay of treatment of macroprolactinomas, its therapeutic usefulness may be limited by poor tolerance, lack of consistent reduction in serum prolactin levels and tumour size, and the necessity for multiple dosing. Consequently new dopamine agonists have been
Prolactinoma: a condition associated with hypoadiponectinemia.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Prolactinomas are prolactin-secreting neoplasias accounting for 40% of the pituitary adenomas. Much is known about the effects of prolactinomas on the reproductive system, but few data are yet available regarding their induced changes on metabolism. This study was aimed at evaluating patients with
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
OBJECTIVE
Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease
Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Hyperprolactinemia is associated with endothelial dysfunction and atherogenic risk factors, but carotid intima media thickness (IMT) has not been studied in hyperprolactinemic patients. To determine whether untreated hyperprolactinemia contributes to increased carotid IMT. Thirty-one prolactinoma
Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Hyperprolactinemia might be related to weight gain, metabolic syndrome (MS), and insulin resistance (IR). Treatment with dopamine agonist (DA) has been shown to reduce body weight and improve metabolic parameters. The objectives of this study were to determine the prevalence of obesity, overweight,
Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
BACKGROUND
Hyperprolactinemia has been associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. This study was designed to assess the anthropometric and metabolic alterations
Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Prolactin is a metabolic hormone. The hypothesis is that hyperprolactinemia can cause metabolic and inflammatory changes which are associated with accelerated atherosclerotic process, but the treatment of hyperprolactinemia with dopamine agonists, leads to reversibility of these processes. The first
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
